Related Experiment Video
Updated: Jun 19, 2026

Primary Culture of Adult Rat Heart Myocytes
Published on: June 16, 2009
Beta-adrenergic receptor signaling in the heart: role of CaMKII
Michael Grimm1, Joan Heller Brown
1Department of Pharmacology, University of California, San Diego, CA, USA. mgrimm@ucsd.edu
Abstract:
The multifunctional Ca(2+)/calmodulin-dependent protein kinase II (CaMKII) targets a number of Ca(2+) homeostatic proteins and regulates gene transcription. Many of the substrates phosphorylated by CaMKII are also substrates for protein kinase A (PKA), the best known downstream effector of beta-adrenergic receptor (beta-AR) signaling. While PKA and CaMKII are conventionally considered to transduce signals through separate pathways, there is a body of evidence suggesting that CaMKII is activated in response to beta-AR stimulation and that some of the downstream effects of beta-AR stimulation are actually mediated by CaMKII. The signaling pathway through which beta-AR stimulation activates CaMKII, in parallel with or downstream of PKA, is not well-defined. This review considers the evidence for and mechanisms by which CaMKII is activated in response to beta-AR stimulation. In addition the potential role of CaMKII in beta-AR regulation of cardiac function is considered. Notably, although many CaMKII targets (e.g., phospholamban or the ryanodine receptor) are central to the regulation of Ca(2+) handling, and effects of CaMKII on Ca(2+) handling are detectable, inhibition or gene deletion of CaMKII has relatively little effect on the acute physiological contractile response to beta-AR. On the other hand CaMKII expression and activity are increased in heart failure, a pathophysiological condition characterized by chronic stimulation of cardiac beta-ARs. Blockade of beta-ARs is an accepted therapy for treatment of chronic heart failure although the rationale for its beneficial effects in cardiomyocytes is uncertain. There is growing evidence that inhibition or gene deletion of CaMKII also has a significant beneficial impact on the development of heart failure. The possibility that excessive beta-AR stimulation is detrimental because of its effects on CaMKII mediated Ca(2+) handling disturbances (e.g., ryanodine receptor phosphorylation and diastolic SR Ca(2+) leak) is an intriguing hypothesis that merits future consideration.
Insights
Calcium/calmodulin-dependent protein kinase II (CaMKII) may mediate some effects of beta-adrenergic receptor (beta-AR) signaling, particularly in heart failure. CaMKII inhibition shows promise for treating heart failure by addressing Ca(2+) handling disturbances.
Area of Science:
- Cardiology
- Molecular Biology
- Biochemistry
Background:
- Ca(2+)/calmodulin-dependent protein kinase II (CaMKII) and protein kinase A (PKA) are key signaling molecules.
- Both kinases target substrates involved in Ca(2+) homeostasis and gene transcription.
- Beta-adrenergic receptor (beta-AR) signaling primarily involves PKA, but CaMKII activation by beta-AR stimulation is increasingly recognized.
Purpose of the Study:
- To review evidence and mechanisms of CaMKII activation by beta-AR stimulation.
- To explore CaMKII's role in beta-AR regulation of cardiac function.
- To consider CaMKII's potential therapeutic targeting in heart failure.
Main Methods:
- Literature review of studies investigating CaMKII and beta-AR signaling.
- Analysis of experimental data on CaMKII activity in response to beta-AR stimulation.
- Examination of the impact of CaMKII inhibition or gene deletion on cardiac function and heart failure models.
Main Results:
- CaMKII is activated by beta-AR stimulation, potentially in parallel or downstream of PKA.
- While acute beta-AR effects on contractility are minimally affected by CaMKII inhibition, CaMKII is upregulated in heart failure.
- CaMKII inhibition or gene deletion demonstrates significant benefits in heart failure development and progression.
Conclusions:
- CaMKII plays a crucial role in the detrimental effects of chronic beta-AR stimulation in heart failure.
- CaMKII-mediated Ca(2+) handling disturbances may underlie heart failure pathophysiology.
- Targeting CaMKII represents a promising therapeutic strategy for heart failure.
Related Concept Videos
Adrenergic Receptors: β Subtype
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors have equal affinities for...
Adrenergic Receptors (Adrenoceptors): Classification
α-Adrenoceptors
α-Adrenoceptors are classified into two main subtypes: α1 and α2. The α1 adrenoceptors, which are found on postsynaptic...
Adrenergic Receptors: ɑ Subtype
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase C—inositol-1,4,5-trisphosphate...
cAMP-dependent Protein Kinase Pathways
G-Protein Gated Ion Channels
Sensory organs,...
Sympathetic Signaling
Sympathetic preganglionic fibers release the neurotransmitter acetylcholine (ACh) onto the ganglionic neurons in the...

